Studies on the genetic abnormality and therapeutic effects and prognosis of multiple myeloma

Studies on the genetic abnormality and therapeutic effects and prognosis of multiple myeloma - NHOH-MMM study/H26-NHO(Hematology)-01

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017005

Enrollment

200

Registered

2015-04-20

Start date

2015-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Untreated symptomatic myeloma more than 20 years at diagnosis 2.Patiets that the initial treatment is possible and survival is expected more than 6 months

Exclusion criteria

Exclusion criteria: 1.Solitary plasmacytoma 2.Patients to use the insurance unapproved drugs to initial treatment 3.Patients that NHOMM study and MARBLE study are not registered

Design outcomes

Primary

Measure	Time frame
Proportion of different genetic abnormalities detected by the MLPA method	—

Secondary

Measure	Time frame
1. Complete response rate with the initial treatment of different genetic abnormalities detected by MLPA method 2. Progression free survival with the initial treatment of different genetic abnormalities detected by MLPA method 3. Overall survival with the initial treatment of different genetic abnormalities detected by MLPA method	—

Countries

Japan

Contacts

Public ContactKazutaka Sunami

National Hospital Organization Okayama Medical Center Department of Hematology

kazusuna@pop12.odn.en.jp086-294-9911

Outcome results